Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety (E01ATCAL0308)
|ClinicalTrials.gov Identifier: NCT00944268|
Recruitment Status : Unknown
Verified July 2009 by Ativus Farmaceutica Ltda.
Recruitment status was: Not yet recruiting
First Posted : July 23, 2009
Last Update Posted : July 24, 2009
To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety.
Clinical study phase III, multicenter, prospective, open.
Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.
|Condition or disease||Intervention/treatment||Phase|
|Anxiety Efficacy Tolerability||Drug: Passiflora, Crataegus e Salix||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||124 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||January 2010|
|Experimental: Liquid and solid||
Drug: Passiflora, Crataegus e Salix
Comparison of different pharmaceutics forms of drug
- Hamilton Scales [ Time Frame: 30 days ]
- Safety evaluation by adverse events relate. [ Time Frame: 30 days ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00944268
|Contact: Dagoberto Brandão||55 11 email@example.com|
|Faculdade de Medicina do ABC||Not yet recruiting|
|Santo André, São Paulo, Brazil, 09060650|
|Contact: Elie Fiss 55 1149935469 firstname.lastname@example.org|
|Principal Investigator: Elie Fiss|
|Principal Investigator:||Elie Fiss||Faculdade de Medicina do ABC|